3
Announcements
Trials
Browse
Landscape
Status
Terminated
1
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Papillomavirus Infections
7
Uterine Cervical Neoplasms
5
Neuroendocrine Tumors
4
Neoplasms
4
Autoimmune Diseases
3
Ovarian Neoplasms
2
Myasthenia Gravis
2
Mesothelioma, Malignant
2
Lung Neoplasms
2
Venous Thrombosis
1
Venous Thromboembolism
1
Uterine Cervical Dysplasia
1
Thyroid Diseases
1
Thrombosis
1
Squamous Intraepithelial Lesions
1
Retinal Telangiectasis
1
Renal Insufficiency
1
Recurrence
1
Prostatic Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Mesothelioma
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphohistiocytosis, Hemophagocytic
1
Leukemia, Hairy Cell
1
Hemorrhage
1
Hematologic Neoplasms
1
Glioma
1
Glioblastoma
1
Interventions
Dexamethasone
362
Bortezomib
231
Lenalidomide
200
Cyclophosphamide
174
Melphalan
154
Calcium Dobesilate
107
Peripheral Blood Stem Cell Transplantation
92
fludarabine phosphate
84
Thalidomide
81
Filgrastim
71
carfilzomib
68
pomalidomide
66
Granulocyte Colony-Stimulating Factor
60
Mycophenolic Acid
59
Busulfan
57
daratumumab
54
Whole-Body Irradiation
54
Tacrolimus
51
ixazomib
50
Prednisone
50
Cyclosporine
49
fludarabine
46
Antilymphocyte Serum
35
Etoposide
30
dexamethasone acetate
29
Methotrexate
29
plerixafor
27
Radiotherapy
26
Doxorubicin
26
dexamethasone 21-phosphate
25
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Multiple Myeloma
×
Data Collection
×
Clear all
NCT03234335
2023-05-06
IRMYG
Centre Hospitalier Universitaire de Saint Etienne
Completed
50 enrolled